Cohen & Steers, Inc. (CNS)
$
76.84
-0.62 (-0.81%)
Key metrics
Financial statements
Free cash flow per share
-0.4999
Market cap
4 Billion
Price to sales ratio
7.2918
Debt to equity
0
Current ratio
20.9145
Income quality
-0.1083
Average inventory
0
ROE
0.3183
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cohen & Steers, Inc. is a publicly owned asset management holding company, identified in the market by the symbol 'CNS'. The firm offers its services through subsidiaries to various institutional investors, including pension funds, endowments, and foundations. The company reported depreciation and amortization expenses of $11,169,000.00 reflecting the wear and tear of its assets. It manages client-focused equity, fixed income, multi-asset, and commodity portfolios, showcasing its diverse investment strategies. The weighted average number of shares outstanding is 50,409,000.00 highlighting the company's shareholder base. Additionally, the cost of revenue for the company is $275,117,000.00 which underscores its production and operational expenses. The firm reported selling, general, and administrative expenses of $60,135,000.00 indicating its operational overhead costs. Established in 1986 and based in New York, with additional offices in London, Hong Kong, Tokyo, and Seattle, Cohen & Steers has a global reach, investing in public equity, fixed income, and commodity markets. Through its subsidiaries, it also focuses on companies in the real estate sector, including real estate investment trusts, as well as in the infrastructure and natural energy resources sectors for both equity and fixed income investments, while also investing in preferred securities. The stock is reasonably priced at $77.46 appealing to a broad range of investors. Despite being a key player in the Asset Management industry, contributing significantly to the overall market landscape, it has a low average trading volume of 219,680.00 indicating lower market activity. With a mid-range market capitalization of $3,917,241,728.00 the company stands as a steady performer in the market. Furthermore, it belongs to the Financial Services sector, driving innovation and growth within the industry. This combination of factors positions Cohen & Steers not only as a reliable investment option but also as an influential participant in the asset management landscape, reinforcing its stability and commitment to its investors.
Is Cohen & Steers, Inc. (CNS) a good investment?
Investing in Cohen & Steers, Inc. (CNS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Cohen & Steers, Inc. (CNS)'s stock forecast?
Analysts predict Cohen & Steers, Inc. stock to fluctuate between $67.96 (low) and $110.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cohen & Steers, Inc.'s market capitalization?
As of 2025-05-30, Cohen & Steers, Inc.'s market cap is $3,917,241,728, based on 50,979,200 outstanding shares.
How does Cohen & Steers, Inc. compare to competitors like JPMorgan Chase & Co.?
Compared to JPMorgan Chase & Co., Cohen & Steers, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Cohen & Steers, Inc. pay dividends?
Cohen & Steers, Inc. pays dividends. The current dividend yield is 2.92%, with a payout of $0.62 per share.
How can I buy Cohen & Steers, Inc. (CNS) stock?
To buy Cohen & Steers, Inc. (CNS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CNS. Place an order (Market, Limit, etc.).
What is the best time to invest in Cohen & Steers, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Cohen & Steers, Inc. perform in the last earnings report?
Revenue: $517,417,000 | EPS: $3 | Growth: 14.50%.
Where can I find Cohen & Steers, Inc.'s investor relations reports?
Visit https://www.cohenandsteers.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cohen & Steers, Inc.?
You can explore historical data from here
What is the all-time high and low for Cohen & Steers, Inc. stock?
All-time high: $110.67 (2024-10-17) | All-time low: $50.05 (2023-10-26).
What are the key trends affecting Cohen & Steers, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Introduces new PerfecTwin ERP Edition with AI capabilities such as real transaction data generation for testing and automated removal of sensitive information Expands collaboration plans with SAP to provide technical enhanced services for cloud ERP advancement Plans to establish ERP delivery center in India to expand global ERP operations CEO Shin Gyoon Hyun joins SAP Sapphire panel session for the second consecutive year to discuss ERP innovation SEOUL, South Korea , May 22, 2025 /PRNewswire/ -- LG CNS, a leading AI transformation (AX) company in Korea, unveiled its latest AI-based ERP testing technology at SAP Sapphire 2025, SAP's annual global conference held in Orlando, Florida. SAP Sapphire brings together industry leaders, customers and partners from around the world to explore the latest technologies and innovations powered by SAP.
businesswire.com
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at ASGCT 2025.
accessnewswire.com
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "Our company remains focused as tightly as ever on neuro-oncology drug development.
accessnewswire.com
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants").
accessnewswire.com
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Management releases "What This Means" segment discussing the receipt of Orphan Drug Designations for TPI 287; Access here HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the successful transfer from Cortice Biosciences, Inc. of Orphan Drug Designation for TPI 287. The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designations for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.
prnewswire.com
NEW YORK , May 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $87.5 billion as of April 30, 2025, a decrease of $70 million from assets under management of $87.6 billion at March 31, 2025. The decrease was due to distributions of $151 million and market depreciation of $60 million, partially offset by net inflows of $141 million.
globenewswire.com
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.
globenewswire.com
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
seekingalpha.com
Cohen & Steers, Inc. (NYSE:CNS ) Q1 2025 Results Conference Call April 17, 2025 10:00 AM ET Company Participants Brian Heller - Senior Vice President & Deputy Corporate Counsel Raja Dakkuri - Chief Financial Officer John Cheigh - President & Chief Investment Officer Joe Harvey - Chief Executive Officer Conference Call Participants John Dunn - Evercore ISI Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers First Quarter 2025 Earnings Conference Call.
prnewswire.com
NEW YORK , April 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended March 31, 2025. The earnings release along with the accompanying earnings presentation can be viewed at Cohen & Steers Reports Results for First Quarter 2025 and on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive.
See all news
